LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

4.1 -2.61

Buy Sell

Overview

Share price change

24h

Current

Min

4.06

Max

4.14

Key metrics
By Trading Economics
Income	5.5M -28M
Sales	8.2M 13M
Profit margin	-208.694
Employees	172
EBITDA	8.7M -27M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+273.9% upside

Dividends
By Dow Jones
Next Earnings	10 mar 2026

Market Stats
By TradingEconomics
Market Cap	-56M 199M
Previous open	6.71
Previous close	4.1

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lut 2026, 23:53 UTC

Hot Stocks

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 lut 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28 lut 2026, 21:36 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 15:20 UTC

Earnings

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 lut 2026, 14:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 14:40 UTC

Major News Events

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

28 lut 2026, 14:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 lut 2026, 13:51 UTC

Major News Events

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

28 lut 2026, 13:47 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 13:44 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 lut 2026, 13:14 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 lut 2026, 12:41 UTC

Major News Events

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

28 lut 2026, 02:32 UTC

Earnings

Acquisitions, Mergers, Takeovers

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 lut 2026, 02:00 UTC

Acquisitions, Mergers, Takeovers

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 lut 2026, 02:00 UTC

Acquisitions, Mergers, Takeovers

Six Months, 9 Offers and $81 Billion. How -2-

28 lut 2026, 00:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 lut 2026, 23:46 UTC

Acquisitions, Mergers, Takeovers

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 lut 2026, 23:33 UTC

Acquisitions, Mergers, Takeovers

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 lut 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

27 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 lut 2026, 21:30 UTC

Earnings

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 lut 2026, 21:30 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 lut 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 lut 2026, 21:17 UTC

Earnings

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 lut 2026, 21:10 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 lut 2026, 21:09 UTC

Acquisitions, Mergers, Takeovers

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 lut 2026, 21:00 UTC

Earnings

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 lut 2026, 20:31 UTC

Acquisitions, Mergers, Takeovers

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 lut 2026, 20:24 UTC

Market Talk

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 lut 2026, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

273.9% upside

12 Months Forecast

Average 15.33 USD 273.9%

High 25 USD

Low 10 USD

Based on 3 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.